Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Taking biosimilars to market
January 2020
SHARING OPTIONS:

INCHEON, Korea—A commercialization agreement began late last year between Samsung Bioepis Co. Ltd. and Biogen for SB11 (ranibizumab) and SB15 (aflibercept) in the U.S., Canada, Europe, Japan and Australia. SB11 is a Phase 3 biosimilar candidate referencing LucentiS, and SB15 is a preclinical biosimilar candidate referencing Eylea. Under the agreement, Biogen has the option to extend the commercialization term for Benepali, Flixabi and Imraldi in Europe for an additional five years. Biogen also has an option to receive commercialization rights to those three biosimilars in China in exchange for royalties on sales in the market. The company will pay Samsung Bioepsis $100 million in upfront payments and up to $270 million in milestone and option payments, and Samsun Bioepis will share sales revenue. Development, regulatory registration and manufacture will fall to Samsung Bioepis, while Biogen will handle commercialization.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.